Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Managing Low & Intermediate Risk Bladder Cancer | BackTable Urology Podcast
NCCN 2026 Bladder Cancer Guidelines Adopt IBCG Risk Stratification ...
SUO 2022: Intermediate Risk Non-Muscle Invasive Bladder Cancer: “New ...
AUA 2025: Active Surveillance for Low-Grade Intermediate Risk Bladder
Improving Intermediate Risk Bladder Cancer: Guidelines, Biomarkers ...
Intermediate Risk Bladder Cancer: Definitions, Patient Care & Treatment ...
AUA 2024: Management of Recurrent Low Grade Intermediate Risk Bladder ...
Intermediate Risk Bladder Cancer: Understanding Your Treatment Options ...
Staging of primary tumors in bladder cancer and risk stratification for ...
Risk of bladder cancer death for low-and intermediate-risk patients ...
Risk stratification of bladder cancer | Download Scientific Diagram
Validation of non‐muscle‐invasive bladder cancer risk stratification ...
AUA 2024: Long Term Outcomes of Low and Intermediate Risk Bladder ...
PPT - Bladder cancer risk factor PowerPoint Presentation, free download ...
Non muscle invasive bladder cancer treatment - WCRJ
Bladder Cancer Academy 2017: AUA Guidelines: Non-Muscle Invasive ...
Urinary Bladder Cancer - Dr Puneet Ahluwalia
Performance of Xpert® Bladder Cancer Monitor in low-, intermediate- and ...
Bladder Cancer Grading
Guidelines for surveillance of nonmuscle invasive bladder cancer 2 ...
(PDF) Intermediate and high-risk non-muscle-invasive bladder cancer: an ...
(PDF) Guidance of adjuvant instillation in intermediate risk non ...
PD30-01: Defining intermediate-risk non-Muscle invasive bladder cancer ...
Low-grade, Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Non–muscle invasive bladder cancer pathways adapted from World J Urol ...
Trial Design Considerations for Intermediate Risk Non Muscle-Invasive ...
Non-Muscle Invasive Bladder Cancer Treatment | Novel Therapies
AUA 2021: AUA Guideline Amendment: Non-Muscle Invasive Bladder Cancer ...
EAU 2024: Defining Intermediate-Risk Non-Muscle Invasive Bladder Cancer ...
Bladder Cancer
Management of Non-Muscle Invasive Bladder Cancer
Overcoming Barriers to Progress in Non-muscle Invasive Bladder Cancer ...
Current Topics in the Management of Non–Muscle-Invasive Bladder Cancer ...
(PDF) Intravesical chemotherapy for intermediate risk non‑muscle ...
SUO 2024: Heterogeneity of Intermediate Risk NMIBC
Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer ...
WSAUA 2025: Treatment of Low Grade Intermediate Risk Non Muscle ...
Intermediate and high-risk non-muscle-invasive bladder cancer: an ...
Bladder Cancer (Carcinoma Bladder) Urology | PPTX
Table 1 from Defining and treating the spectrum of intermediate risk ...
Low-Grade Intermediate-Risk Non–Muscle-Invasive Bladder Cancer
The International Bladder Cancer Group Intermediate-Risk Non-muscle ...
Bladder Cancer Guidelines - Cancer Therapy Advisor
Muscle Invasive Bladder Cancer Prognosis Non Muscle Invasive Bladder
EAU Guidelines on Non-muscle-invasive Bladder Cancer - Urology Cheatsheets
The Latest Research on Bladder Cancer - UroToday
Bladder Cancer: Non-Muscle Invasive Guideline - American Urological ...
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus ...
Intermediate-risk Non–muscle-invasive Bladder Cancer: Recommendations ...
Non-Muscle-Invasive Bladder Cancer: Review of Diagnosis and Management ...
Non-muscle Invasive Bladder Cancer: Diagnosis & Treatment
Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder ...
SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate ...
Ca Urinary Bladder anatomy to management | PPTX
Table 1 from The management of non-muscle-invasive bladder cancer: A ...
Experimental and New Approaches For Bladder Preservation in ...
Guideline recommendation for low-risk non-muscle-invasive bladder ...
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder ...
FDA Approves Zusduri (Mitomycin) for Recurrent Low-Grade Intermediate ...
Noninvasive Bladder Cancer: Diagnosis and Management | MDedge
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in ...
Urinary bladder
Impact of Pathologic Re-Review on Grade, Clinical Stage, and Risk ...
Table 1 from Intravesical Therapy for Non-muscle Invasive Bladder ...
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022 in: Journal ...
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment ...
MP13-17 CHARACTERIZING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER ...
Bladder Cancer: Types, Causes, Symptoms, Diagnosis & Treatment
Understanding Non Muscle Invasive Bladder Cancer: Symptoms, Diagnosis ...
Chemohyperthermia with Mitomycin C and COMBAT system in High Risk Non ...
Improving Knowledge of Surveillance Practices in Non-muscle Invasive ...
Guideline definitions of low-, intermediate- and high-risk ...
Recommendations for Managing Intermediate-Risk NMIBC | www ...
Proposed substratification of intermediate-risk non-muscle-invasive ...
NMIBC - URORESIDENT.COM
SUO 2023: Treatment of Low-grade, Intermediate-risk Non-muscle Invasive ...
Reviews in Urology Volume 24, Issue 4 2025UGN-102 in Intermediate-Risk ...
UGN-102 Chemoablation for Recurrent Low-Grade Nonmuscle-Invasive ...
(PDF) The optimal intravesical maintenance chemotherapy scheme for the ...
(PDF) Guidance of adjuvant instillation in intermediate-risk non-muscle ...
(PDF) Intravesical Therapy in Patients with Intermediate-risk Non ...
Clinical Practice Recommendations for the Management of Non–Muscle ...
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive ...
ASCO GU 2021: Deintensification of Management of Low-Risk Non-Muscle ...
Clinical Validation of the Intermediate-risk Non–muscle-invasive ...
AUA 2025: Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle ...
(PDF) Intensive Intravesical Mitomycin C Therapy in Non-Muscle-Invasive ...
ASCO 2025: Duration of Response Following Treatment with UGN-102 in ...
Recent advancements in the diagnosis and treatment of non‐muscle ...
Refining Active Surveillance Eligibility in Intermediate-risk Non ...
Intravesical Therapy in Patients with Intermediate-risk Non–muscle ...
Intravesical gemcitabine/docetaxel as an alternative therapy for ...
ASCO 2025: Impact of Tumor Burden or Focality in Recurrent Low-Grade ...
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle ...
Recirculant Hyperthermic IntraVEsical Chemotherapy HIVEC in ...
AUA 2024: Role of Urinary Markers in Surveillance of NMIBC Patients
Prognostic Implications of Treatment Delays for Patients with Non ...
